Test Your Knowledge (Answers): Pharma Development & Outsourcing Innovation
Key Takeaways
- Bioreactor portfolios of 1,000–15,000 L (including 5,000 and 10,000 L steps) are positioned to de-risk scale transitions while preserving comparability and regulatory rigor.
- FDA’s Emerging Technology Program is anchored in early sponsor–agency interaction to surface implementation barriers pre-submission; graduation occurs after sufficient shared experience with the technology.
Think you know the ins and outs of pharma development and outsourcing? See how you did on the quiz!
1. To ensure seamless scale transitions and mitigate regulatory continuity risks, what range of bioreactor capacities is typically cited as essential for a modern biologics manufacturing facility?
A. 100 to 500 liters
B. 1,000 to 15,000 liters
C. 50 to 250 liters
D. 20,000 to 50,000 liters
Explanation: Having a range from 1,000 to 15,000 liters (including 5,000 and 10,000 liter increments) allows for scalable transitions that maintain regulatory rigor.¹
2. According to the FDA, what is the “hallmark” of the Emerging Technology Program designed to support innovative manufacturing?
A. Provision of federal grants to small biotechs developing novel mRNA delivery systems.
B. Early engagement between the industry and the cross-functional Emerging Technology team.
C. Elimination of onsite inspections for facilities using single-use bioreactor systems.
D. Automatic approval for any application utilizing AI-driven process modeling.
Explanation: Early engagement allows companies to identify and resolve roadblocks to technology implementation before they submit a formal drug application.²
3. In the context of Explainable AI, what is the defining characteristic of post-hoc explainability techniques like SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-agnostic Explanations)?
A. They are used to train inherently transparent models, such as decision trees, from the start.
B. They guarantee that a deep learning model will reach 100% predictive accuracy.
C. They eliminate the need for human subject matter experts in the governance framework.
D. They provide insights into the internal logic of a model after it has already been trained.
Explanation: Post-hoc techniques approximate the behavior of complex models to provide feature importance or justifications for specific predictions.³
4. How do advanced analytics and process modeling improve decision quality during the early stages of drug development?
A. By replacing experimental design with purely theoretical simulations to save costs.
B. By providing a “black-box” output that requires no interpretation from technical teams.
C. By ensuring that clinical trial enrollment rates remain static regardless of market conditions.
D. By allowing teams to test assumptions and evaluate scale-up feasibility before downstream commitments are locked in.
Explanation: Multivariate analysis allows for the quantification of uncertainty and evaluation of raw material sensitivity early in the process.⁴
5. The manufacturing of antibody-drug conjugates (ADCs) is cited as a primary example of which industry trend?
A. The shift toward using only large-scale 15,000-liter stainless steel bioreactors.
B. The return to traditional small-molecule manufacturing paradigms.
C. The complete automation of drug delivery systems without human oversight.
D. The convergence of biologics- and chemistry-driven manufacturing processes.
Explanation: ADCs require specialized facilities that can handle both the biological component (the antibody) and the chemical component (the payload/linker).¹
6. Which of the following describes the “Three S” principles that serve as the operational foundation for collaborative CDMO partnerships?
A. Simplification, standardization, and scalability
B. Specialization, secrecy, and solvency
C. Speed, security, and sustainability
D. Sourcing, synthesis, and stability
Explanation: These three principles ensure predictable performance, reproducible outcomes, and the ability to respond to evolving demand.¹
7. Under the FDA's Emerging Technology Program, when does a specific technology 'graduate' from the program?
A. When the technology is replaced by a newer, more innovative manufacturing method.
B. As soon as the first clinical trial associated with the technology is completed.
C. When the company receives its first $100 million in commercial revenue.
D. When the FDA and the industry have gained sufficient experience with the technology.
Explanation: Once sufficient experience is gained, future applications using that technology can follow the standard quality assessment process.²
8. Why is “digital maturity” becoming a key criterion for biotech leaders when selecting a CDMO partner
A. It allows for the use of digital twins and predictive analytics to optimize processes and maintenance.
B. It ensures that the CDMO will only use paper-based documentation to prevent cyberattacks.
C. It focuses solely on social media presence to attract clinical trial participants.
D. It eliminates the need for regulatory inspections by automating compliance reports.
Explanation: Digitally mature CDMOs use tools like AI-driven optimization and process modeling to improve throughput and reduce risk.⁵
9. What is the primary motivation for CDMOs to invest in workforce and facility capacity ahead of projected demand?
A. To ensure that all manufacturing processes remain at the 200-liter lab scale.
B. To increase the total carbon footprint of the facility for tax incentives.
C. To mitigate the lag between clinical approval and market launch, ensuring supply continuity.
D. To comply with the EU's “right to explanation” regulation regarding AI.
Explanation: Proactive capacity planning eliminates reactive expansion delays and ensures immediate readiness for client onboarding when demand spikes.¹
10. In the context of CDMO evolution, what does the “single source of truth” concept refer to?
A. The idea that only small biotechs have accurate data for early-stage development.
B. A marketing slogan used to promote the acquisition of CROs by larger pharma companies.
C. A regulatory requirement that only one person is allowed to sign off on batch records.
D. A shared data platform that integrates development, clinical research, and manufacturing information.
Explanation: This reduces communication silos and handoff risks by ensuring all stakeholders have access to the same consistent and up-to-date data.⁵
References
- Sharp, K. Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development. BioPharm International. January 16, 2026.
https://www.biopharminternational.com/view/transactional-collaborative-partnerships-rapid-flexible-biologics-development - FDA. Emerging Technology Program (ETP). FDA.gov. Dec. 17, 2025.
https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/emerging-technology-program-etp - Antony, T. J. P., Kamakshi, V., & Anandapriya, B. The Rise of Explainable AI: Trends in Interpretability for Machine Learning Models. Nanotechnology Perceptions, 2023.
https://nano-ntp.com/index.php/nano/article/download/4085/3111/7745#:~:text=The%20Importance%20of%20Explainability%20in,confidence%20in%20AI%2Ddriven%20systems - From Transactional to Integrated: How Innovation Is Reshaping Outsourced Development and Manufacturing. Pharm Technol. 2026;50:8-11. Accessed February 25, 2026.
https://www.pharmtech.com/view/from-transactional-to-integrated-how-innovation-is-reshaping-outsourced-development-and-manufacturing - Ro, J. From Outsourcing to Integration: How CDMOs Have Evolved Over Time. October 27, 2025.
https://www.thermofisher.com/blog/biotechnology/from-outsourcing-to-integration-how-cdmos-have-evolved-over-time/